Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-403|1|n/a|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4728|1|280|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4729|1|331|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4730|1|377|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4731|1|434|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4732|1|435|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4733|1|444|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4734|1|444|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4735|1|477|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4736|1|493|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4737|1|507|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4738|1|518|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4739|1|524|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4740|1|527|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4741|1|546|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4742|1|552|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4743|1|560|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4744|1|560|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4745|1|560|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4746|1|561|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4747|1|561|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4748|1|566|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4749|1|566|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4750|1|566|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4751|1|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4752|1|568|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4753|1|570|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4754|1|575|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4755|1|576|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4756|1|581|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4757|1|587|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4758|1|595|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4759|1|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4760|1|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4761|1|611|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4762|1|616|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4763|1|616|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4764|1|621|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4765|1|622|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4766|1|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4767|1|625|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4768|1|629|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4769|1|643|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4770|1|646|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4771|1|647|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4772|1|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4773|1|657|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4774|1|657|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4775|1|657|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4776|1|658|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4777|1|660|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4778|1|665|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4779|1|665|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4780|1|667|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4781|1|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4782|1|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4783|1|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4784|1|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4785|1|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4786|1|674|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4787|1|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4788|1|674|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4789|1|675|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LSAR,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4790|1|677|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4791|1|678|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4792|1|681|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4793|1|681|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4794|1|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4795|1|685|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4796|1|685|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4797|1|685|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4798|1|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4799|1|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4800|1|693|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4801|1|693|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4802|1|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4803|1|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4804|1|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4805|1|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4806|1|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4807|1|706|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4808|1|708|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4809|1|713|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4810|1|714|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4811|1|714|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4812|1|715|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4813|1|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4814|1|715|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4815|1|716|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4816|1|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4817|1|717|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4818|1|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4819|1|721|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4820|1|721|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4821|1|722|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4822|1|722|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4823|1|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4824|1|727|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4825|1|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4826|1|730|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4827|1|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4828|1|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4829|1|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4830|1|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4831|1|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4832|1|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4833|1|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4834|1|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4835|1|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4836|1|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4837|1|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4838|1|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4839|1|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4840|1|749|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4841|1|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4842|1|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4843|1|753|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4844|1|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4845|1|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4846|1|757|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4847|1|762|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4848|1|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4849|1|764|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4850|1|765|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4851|1|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4852|1|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4853|1|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4854|1|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4855|1|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4856|1|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4857|1|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4858|1|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4859|1|779|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4860|1|783|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4861|1|784|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4862|1|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4863|1|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4864|1|785|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4865|1|786|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4866|1|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4867|1|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4868|1|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4869|1|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4870|1|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4871|1|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4872|1|791|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4873|1|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4874|1|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4875|1|791|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4876|1|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4877|1|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4878|1|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4879|1|792|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4880|1|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4881|1|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4882|1|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4883|1|797|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4884|1|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4885|1|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4886|1|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4887|1|800|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4888|1|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4889|1|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4890|1|801|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4891|1|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4892|1|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4893|1|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4894|1|803|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4895|1|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4896|1|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4897|1|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4898|1|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4899|1|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4900|1|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4901|1|810|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4902|1|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4903|1|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4904|1|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4905|1|811|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4906|1|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4907|1|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4908|1|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4909|1|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4910|1|814|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4911|1|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4912|1|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4913|1|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4914|1|818|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4915|1|818|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4916|1|818|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4917|1|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4918|1|820|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4919|1|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4920|1|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4921|1|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4922|1|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4923|1|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4924|1|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4925|1|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4926|1|827|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4927|1|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4928|1|828|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4929|1|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4930|1|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4931|1|830|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4932|1|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4933|1|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4934|1|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4935|1|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4936|1|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4937|1|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4938|1|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4939|1|839|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4940|1|841|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4941|1|842|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4942|1|846|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4943|1|846|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4944|1|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4945|1|847|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4946|1|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4947|1|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4948|1|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4949|1|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4950|1|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4951|1|851|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4952|1|852|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4953|1|853|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4954|1|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4955|1|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4956|1|853|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4957|1|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4958|1|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4959|1|858|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4960|1|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4961|1|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4962|1|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4963|1|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4964|1|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4965|1|861|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4966|1|862|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4967|1|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4968|1|864|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4969|1|865|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4970|1|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4971|1|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4972|1|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4973|1|869|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4974|1|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4975|1|871|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4976|1|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4977|1|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4978|1|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4979|1|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4980|1|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4981|1|876|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4982|1|877|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4983|1|878|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4984|1|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4985|1|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4986|1|879|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4987|1|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4988|1|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4989|1|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4990|1|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4991|1|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4992|1|888|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4993|1|889|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4994|1|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4995|1|892|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4996|1|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4997|1|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4998|1|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-4999|1|895|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5000|1|897|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5001|1|899|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5002|1|901|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5003|1|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5004|1|902|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5005|1|903|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5006|1|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5007|1|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5008|1|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5009|1|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5010|1|906|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5011|1|907|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5012|1|908|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5013|1|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5014|1|911|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5015|1|911|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5016|1|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5017|1|913|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5018|1|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5019|1|914|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5020|1|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5021|1|915|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5022|1|915|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5023|1|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5024|1|916|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5025|1|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5026|1|916|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5027|1|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5028|1|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5029|1|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5030|1|920|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5031|1|921|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5032|1|923|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5033|1|923|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5034|1|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5035|1|925|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5036|1|925|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5037|1|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5038|1|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5039|1|930|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5040|1|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5041|1|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5042|1|934|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5043|1|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5044|1|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5045|1|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5046|1|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5047|1|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5048|1|937|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5049|1|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5050|1|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5051|1|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5052|1|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5053|1|938|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5054|1|941|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5055|1|944|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5056|1|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5057|1|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5058|1|945|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5059|1|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5060|1|946|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5061|1|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5062|1|947|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5063|1|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5064|1|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5065|1|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5066|1|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5067|1|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5068|1|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5069|1|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5070|1|951|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5071|1|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5072|1|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5073|1|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5074|1|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5075|1|953|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5076|1|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5077|1|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5078|1|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5079|1|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5080|1|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5081|1|960|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5082|1|960|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5083|1|960|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5084|1|961|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5085|1|962|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5086|1|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5087|1|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5088|1|966|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5089|1|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5090|1|967|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5091|1|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5092|1|967|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5093|1|968|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5094|1|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5095|1|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5096|1|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5097|1|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5098|1|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5099|1|973|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5100|1|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5101|1|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5102|1|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5103|1|975|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5104|1|977|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5105|1|977|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5106|1|981|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5107|1|981|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5108|1|981|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5109|1|983|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5110|1|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5111|1|984|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5112|1|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5113|1|989|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5114|1|991|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5115|1|991|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5116|1|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5117|1|993|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5118|1|993|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5119|1|994|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5120|1|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5121|1|997|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5122|1|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5123|1|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5124|1|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5125|1|1000|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5126|1|1000|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5127|1|1000|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5128|1|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5129|1|1002|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5130|1|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5131|1|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5132|1|1004|Neoplasia benign|Endocrine system|THARA|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5133|1|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5134|1|1004|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5135|1|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5136|1|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5137|1|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5138|1|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5139|1|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5140|1|1009|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5141|1|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5142|1|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5143|1|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5144|1|1016|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5145|1|1018|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5146|1|1021|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5147|1|1021|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5148|1|1022|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5149|1|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5150|1|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5151|1|1024|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5152|1|1025|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5153|1|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5154|1|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5155|1|1031|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5156|1|1031|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5157|1|1031|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5158|1|1032|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5159|1|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5160|1|1036|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5161|1|1037|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5162|1|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5163|1|1042|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5164|1|1042|Neoplasia benign|Endocrine system|THARA|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5165|1|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5166|1|1042|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5167|1|1043|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5168|1|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5169|1|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5170|1|1044|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5171|1|1046|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5172|1|1049|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5173|1|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5174|1|1052|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5175|1|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5176|1|1055|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5177|1|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5178|1|1056|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5179|1|1058|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5180|1|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5181|1|1063|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5182|1|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5183|1|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5184|1|1070|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5185|1|1070|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5186|1|1070|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5187|1|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5188|1|1077|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5189|1|1077|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5190|1|1077|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5191|1|1078|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5192|1|1079|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5193|1|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5194|1|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5195|1|1080|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5196|1|1084|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5197|1|1084|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5198|1|1084|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5199|1|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5200|1|1088|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5201|1|1088|Neoplasia benign|Endocrine system|THARA|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5202|1|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5203|1|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5204|1|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5205|1|1095|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5206|1|1098|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5207|1|1100|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5208|1|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5209|1|1108|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5210|1|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5211|1|1116|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5212|1|1127|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5213|1|1134|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5214|1|1134|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5215|1|1168|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5216|1|1182|Other deterministic changes|Whole body|NVL|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5217|1|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-1|C57BL/6 female mice control group,B6FCONT|1|70|none (controls)|0|grays|External exposure|n/a|491 (492 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-1-5218|1|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5219|2|325|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5220|2|436|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5221|2|443|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5222|2|451|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5223|2|487|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5224|2|521|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5225|2|524|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5226|2|531|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5227|2|538|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5228|2|542|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5229|2|545|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5230|2|552|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5231|2|559|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5232|2|559|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5233|2|566|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5234|2|569|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5235|2|570|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5236|2|577|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5237|2|582|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5238|2|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5239|2|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5240|2|601|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5241|2|603|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5242|2|604|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5243|2|605|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5244|2|616|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5245|2|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5246|2|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5247|2|637|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5248|2|640|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5249|2|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LSAR,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5250|2|654|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5251|2|665|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5252|2|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5253|2|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5254|2|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5255|2|685|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5256|2|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5257|2|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5258|2|694|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5259|2|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5260|2|706|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5261|2|708|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5262|2|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5263|2|713|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5264|2|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5265|2|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5266|2|723|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5267|2|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5268|2|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5269|2|727|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5270|2|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5271|2|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5272|2|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5273|2|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5274|2|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5275|2|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5276|2|750|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5277|2|751|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5278|2|754|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5279|2|755|Neoplasia systemic|Haematolymphatic system|LMYL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5280|2|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5281|2|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5282|2|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5283|2|757|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5284|2|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5285|2|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5286|2|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5287|2|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5288|2|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5289|2|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5290|2|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5291|2|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5292|2|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5293|2|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5294|2|779|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5295|2|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5296|2|783|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5297|2|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5298|2|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5299|2|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5300|2|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5301|2|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5302|2|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5303|2|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5304|2|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5305|2|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5306|2|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5307|2|797|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5308|2|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5309|2|797|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5310|2|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5311|2|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5312|2|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5313|2|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5314|2|806|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5315|2|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5316|2|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5317|2|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5318|2|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5319|2|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5320|2|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5321|2|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5322|2|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5323|2|817|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5324|2|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5325|2|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5326|2|820|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5327|2|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5328|2|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5329|2|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5330|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5331|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5332|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5333|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5334|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5335|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5336|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5337|2|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5338|2|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5339|2|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5340|2|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5341|2|831|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5342|2|832|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5343|2|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5344|2|834|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5345|2|839|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5346|2|844|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5347|2|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5348|2|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5349|2|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5350|2|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5351|2|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5352|2|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5353|2|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5354|2|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5355|2|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5356|2|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5357|2|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5358|2|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5359|2|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5360|2|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5361|2|858|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5362|2|858|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5363|2|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5364|2|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5365|2|860|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5366|2|860|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5367|2|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5368|2|861|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5369|2|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5370|2|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5371|2|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5372|2|867|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5373|2|868|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5374|2|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5375|2|869|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5376|2|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5377|2|871|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5378|2|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5379|2|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5380|2|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5381|2|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5382|2|876|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5383|2|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5384|2|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5385|2|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5386|2|878|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5387|2|878|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5388|2|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5389|2|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5390|2|879|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5391|2|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5392|2|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5393|2|879|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5394|2|881|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5395|2|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5396|2|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5397|2|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5398|2|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5399|2|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5400|2|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5401|2|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5402|2|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5403|2|885|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5404|2|887|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5405|2|889|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5406|2|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5407|2|890|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5408|2|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5409|2|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5410|2|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5411|2|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5412|2|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5413|2|892|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5414|2|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5415|2|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5416|2|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5417|2|895|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5418|2|895|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5419|2|896|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5420|2|897|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5421|2|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5422|2|898|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5423|2|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5424|2|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5425|2|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5426|2|902|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5427|2|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5428|2|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5429|2|903|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5430|2|904|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5431|2|905|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5432|2|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5433|2|906|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5434|2|906|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5435|2|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5436|2|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5437|2|907|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5438|2|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5439|2|909|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5440|2|909|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5441|2|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5442|2|909|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5443|2|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5444|2|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5445|2|910|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5446|2|910|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5447|2|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5448|2|912|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5449|2|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5450|2|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5451|2|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5452|2|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5453|2|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5454|2|916|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5455|2|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5456|2|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5457|2|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5458|2|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5459|2|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5460|2|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5461|2|924|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5462|2|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5463|2|925|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5464|2|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5465|2|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5466|2|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5467|2|928|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5468|2|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5469|2|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5470|2|930|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5471|2|931|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5472|2|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5473|2|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5474|2|932|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5475|2|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5476|2|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5477|2|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5478|2|933|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5479|2|933|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5480|2|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5481|2|935|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5482|2|936|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5483|2|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5484|2|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5485|2|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5486|2|937|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5487|2|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5488|2|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5489|2|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5490|2|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5491|2|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5492|2|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5493|2|941|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5494|2|942|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5495|2|942|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5496|2|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5497|2|943|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5498|2|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5499|2|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5500|2|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5501|2|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5502|2|946|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5503|2|946|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5504|2|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5505|2|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5506|2|949|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5507|2|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5508|2|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5509|2|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5510|2|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5511|2|951|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5512|2|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5513|2|951|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5514|2|951|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5515|2|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5516|2|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5517|2|952|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5518|2|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5519|2|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5520|2|954|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5521|2|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5522|2|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5523|2|955|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5524|2|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5525|2|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5526|2|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5527|2|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5528|2|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5529|2|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5530|2|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5531|2|961|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5532|2|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5533|2|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5534|2|965|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5535|2|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5536|2|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5537|2|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5538|2|970|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5539|2|972|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5540|2|972|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5541|2|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5542|2|974|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5543|2|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5544|2|974|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5545|2|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5546|2|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5547|2|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5548|2|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5549|2|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5550|2|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5551|2|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5552|2|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5553|2|979|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5554|2|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5555|2|980|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5556|2|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5557|2|981|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5558|2|982|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5559|2|982|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5560|2|982|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5561|2|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5562|2|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5563|2|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5564|2|983|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5565|2|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5566|2|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5567|2|983|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5568|2|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5569|2|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5570|2|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5571|2|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5572|2|987|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5573|2|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5574|2|987|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5575|2|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5576|2|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5577|2|989|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5578|2|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5579|2|990|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5580|2|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5581|2|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5582|2|991|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5583|2|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5584|2|993|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5585|2|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5586|2|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5587|2|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5588|2|995|Neoplasia benign|Endocrine system|THARA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5589|2|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5590|2|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5591|2|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5592|2|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5593|2|997|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5594|2|999|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5595|2|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5596|2|1001|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5597|2|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5598|2|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5599|2|1002|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5600|2|1002|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5601|2|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5602|2|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5603|2|1004|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5604|2|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5605|2|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5606|2|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5607|2|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5608|2|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5609|2|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5610|2|1010|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5611|2|1011|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5612|2|1012|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5613|2|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5614|2|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5615|2|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5616|2|1016|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5617|2|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5618|2|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5619|2|1019|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5620|2|1021|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5621|2|1021|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5622|2|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5623|2|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5624|2|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5625|2|1022|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5626|2|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5627|2|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5628|2|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5629|2|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5630|2|1025|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5631|2|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5632|2|1028|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5633|2|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5634|2|1028|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5635|2|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5636|2|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5637|2|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5638|2|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5639|2|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5640|2|1032|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5641|2|1032|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5642|2|1034|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5643|2|1035|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5644|2|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5645|2|1035|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5646|2|1035|Neoplasia benign|Endocrine system|THARA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5647|2|1035|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5648|2|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5649|2|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5650|2|1036|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5651|2|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5652|2|1036|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5653|2|1037|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5654|2|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5655|2|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5656|2|1038|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5657|2|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5658|2|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5659|2|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5660|2|1044|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5661|2|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5662|2|1051|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5663|2|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5664|2|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5665|2|1053|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5666|2|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5667|2|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5668|2|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5669|2|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5670|2|1059|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5671|2|1059|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5672|2|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5673|2|1060|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5674|2|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5675|2|1063|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5676|2|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5677|2|1064|Neoplasia benign|Endocrine system|THARA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5678|2|1064|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5679|2|1067|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5680|2|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5681|2|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5682|2|1071|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5683|2|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5684|2|1071|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TADR,MPATH: 549 - carcinoma|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5685|2|1072|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5686|2|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5687|2|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5688|2|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5689|2|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5690|2|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5691|2|1077|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5692|2|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5693|2|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5694|2|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5695|2|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5696|2|1081|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5697|2|1085|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5698|2|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5699|2|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5700|2|1096|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5701|2|1097|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5702|2|1098|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5703|2|1098|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5704|2|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5705|2|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5706|2|1099|Neoplasia benign|Endocrine system|THARA|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5707|2|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5708|2|1102|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5709|2|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5710|2|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5711|2|1113|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5712|2|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5713|2|1122|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5714|2|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5715|2|1128|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5716|2|1129|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5717|2|1137|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5718|2|1143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5719|2|1151|Other deterministic changes|Whole body|NVL|
1007-2-2|C57BL/6 male mice control group,B6MCONT|1|70|none (controls)|0|grays|External exposure|n/a|502 (502 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-2-5720|2|1168|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5721|3|282|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5722|3|318|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5723|3|350|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5724|3|365|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5725|3|399|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5726|3|399|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5727|3|429|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5728|3|442|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5729|3|444|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5730|3|469|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5731|3|469|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5732|3|469|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5733|3|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5734|3|486|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5735|3|492|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5736|3|499|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5737|3|511|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5738|3|525|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5739|3|527|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5740|3|559|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5741|3|560|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5742|3|564|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5743|3|567|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5744|3|583|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5745|3|583|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5746|3|605|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5747|3|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5748|3|626|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5749|3|636|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5750|3|636|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5751|3|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5752|3|643|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5753|3|643|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5754|3|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5755|3|664|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5756|3|664|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5757|3|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5758|3|667|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5759|3|671|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5760|3|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5761|3|681|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5762|3|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5763|3|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5764|3|694|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5765|3|694|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5766|3|699|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5767|3|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5768|3|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5769|3|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5770|3|719|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5771|3|734|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5772|3|735|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5773|3|736|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5774|3|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5775|3|738|Neoplasia benign|Endocrine system|THARA|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5776|3|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5777|3|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5778|3|749|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5779|3|751|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5780|3|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5781|3|756|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5782|3|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5783|3|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5784|3|762|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5785|3|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5786|3|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5787|3|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5788|3|769|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5789|3|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5790|3|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5791|3|787|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5792|3|790|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5793|3|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5794|3|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5795|3|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5796|3|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5797|3|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5798|3|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5799|3|804|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5800|3|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5801|3|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5802|3|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5803|3|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5804|3|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5805|3|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5806|3|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5807|3|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5808|3|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5809|3|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5810|3|826|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5811|3|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5812|3|832|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5813|3|832|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5814|3|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5815|3|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5816|3|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5817|3|836|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5818|3|841|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5819|3|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5820|3|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5821|3|843|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5822|3|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5823|3|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5824|3|853|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5825|3|855|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5826|3|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5827|3|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5828|3|859|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5829|3|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5830|3|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5831|3|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5832|3|867|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5833|3|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5834|3|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5835|3|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5836|3|871|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5837|3|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5838|3|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5839|3|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5840|3|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5841|3|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5842|3|875|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5843|3|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5844|3|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5845|3|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5846|3|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5847|3|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5848|3|879|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5849|3|881|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5850|3|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5851|3|884|Neoplasia benign|Endocrine system|THARA|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5852|3|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5853|3|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5854|3|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5855|3|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5856|3|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5857|3|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5858|3|895|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5859|3|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5860|3|896|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5861|3|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5862|3|902|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5863|3|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5864|3|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5865|3|912|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5866|3|913|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5867|3|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5868|3|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5869|3|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5870|3|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5871|3|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5872|3|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5873|3|930|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5874|3|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5875|3|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5876|3|931|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5877|3|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5878|3|937|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5879|3|941|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5880|3|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5881|3|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5882|3|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5883|3|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5884|3|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5885|3|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5886|3|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5887|3|949|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5888|3|950|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5889|3|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5890|3|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5891|3|952|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5892|3|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5893|3|954|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5894|3|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5895|3|958|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5896|3|959|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5897|3|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5898|3|965|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5899|3|965|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5900|3|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5901|3|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5902|3|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5903|3|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5904|3|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5905|3|976|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5906|3|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5907|3|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5908|3|980|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5909|3|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5910|3|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5911|3|983|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5912|3|986|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5913|3|987|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5914|3|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5915|3|995|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5916|3|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5917|3|997|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5918|3|997|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5919|3|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5920|3|1000|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5921|3|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5922|3|1001|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5923|3|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5924|3|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5925|3|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5926|3|1015|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5927|3|1015|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5928|3|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5929|3|1016|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5930|3|1017|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5931|3|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5932|3|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5933|3|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5934|3|1028|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5935|3|1029|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5936|3|1029|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5937|3|1033|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5938|3|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5939|3|1035|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5940|3|1036|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5941|3|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5942|3|1043|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5943|3|1045|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5944|3|1045|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5945|3|1046|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5946|3|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5947|3|1051|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5948|3|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5949|3|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5950|3|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5951|3|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5952|3|1067|Neoplasia benign|Endocrine system|THARA|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5953|3|1068|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5954|3|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5955|3|1072|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5956|3|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5957|3|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5958|3|1074|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5959|3|1080|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5960|3|1084|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5961|3|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5962|3|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5963|3|1093|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5964|3|1098|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5965|3|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5966|3|1108|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5967|3|1112|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5968|3|1112|Other deterministic changes|Whole body|NVL|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5969|3|1113|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5970|3|1114|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5971|3|1119|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5972|3|1150|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TADR,MPATH: 549 - carcinoma|
1007-2-3|C57BL/6 female mice 0.5 Gy exposure at 10 weeks,B6F50A|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|253 (253 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-3-5973|3|1168|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5974|4|352|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5975|4|433|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5976|4|486|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5977|4|528|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5978|4|556|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5979|4|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5980|4|595|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5981|4|624|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5982|4|624|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5983|4|629|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5984|4|651|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5985|4|657|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5986|4|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5987|4|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5988|4|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5989|4|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5990|4|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5991|4|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5992|4|709|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5993|4|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5994|4|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5995|4|720|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5996|4|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5997|4|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5998|4|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-5999|4|727|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6000|4|736|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6001|4|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6002|4|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6003|4|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6004|4|749|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6005|4|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6006|4|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6007|4|752|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6008|4|758|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6009|4|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6010|4|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6011|4|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6012|4|770|Neoplasia malignant|Endocrine system|THARC|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6013|4|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6014|4|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6015|4|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6016|4|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6017|4|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6018|4|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6019|4|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6020|4|795|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6021|4|798|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6022|4|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6023|4|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6024|4|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6025|4|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6026|4|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6027|4|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6028|4|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6029|4|814|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6030|4|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6031|4|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6032|4|827|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6033|4|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6034|4|835|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6035|4|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6036|4|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6037|4|839|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6038|4|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6039|4|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6040|4|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6041|4|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6042|4|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6043|4|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6044|4|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6045|4|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6046|4|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6047|4|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6048|4|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6049|4|850|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6050|4|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6051|4|855|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6052|4|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6053|4|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6054|4|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6055|4|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6056|4|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6057|4|864|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6058|4|867|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6059|4|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6060|4|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6061|4|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6062|4|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6063|4|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6064|4|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6065|4|877|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6066|4|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6067|4|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6068|4|883|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6069|4|883|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6070|4|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6071|4|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6072|4|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6073|4|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6074|4|893|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6075|4|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6076|4|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6077|4|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6078|4|896|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6079|4|899|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6080|4|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6081|4|900|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6082|4|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6083|4|904|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6084|4|904|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6085|4|906|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6086|4|908|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6087|4|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6088|4|909|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6089|4|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6090|4|911|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6091|4|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6092|4|916|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6093|4|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6094|4|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6095|4|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6096|4|919|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6097|4|920|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6098|4|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6099|4|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6100|4|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6101|4|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6102|4|925|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6103|4|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6104|4|926|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6105|4|928|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6106|4|929|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6107|4|930|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6108|4|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6109|4|931|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6110|4|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6111|4|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6112|4|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6113|4|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6114|4|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6115|4|940|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6116|4|940|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6117|4|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6118|4|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6119|4|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6120|4|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6121|4|946|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6122|4|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6123|4|948|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6124|4|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6125|4|951|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6126|4|951|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6127|4|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6128|4|958|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6129|4|959|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6130|4|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6131|4|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6132|4|965|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6133|4|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6134|4|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6135|4|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6136|4|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6137|4|972|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6138|4|972|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6139|4|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6140|4|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6141|4|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6142|4|979|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6143|4|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6144|4|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6145|4|979|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6146|4|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6147|4|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6148|4|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6149|4|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6150|4|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6151|4|986|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6152|4|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6153|4|991|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6154|4|997|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6155|4|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6156|4|1000|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6157|4|1000|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6158|4|1004|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6159|4|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6160|4|1005|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6161|4|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6162|4|1006|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6163|4|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6164|4|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6165|4|1011|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6166|4|1011|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6167|4|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6168|4|1014|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6169|4|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6170|4|1015|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6171|4|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6172|4|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6173|4|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6174|4|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6175|4|1023|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6176|4|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6177|4|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6178|4|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6179|4|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6180|4|1035|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6181|4|1035|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6182|4|1039|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6183|4|1039|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6184|4|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6185|4|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6186|4|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6187|4|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6188|4|1042|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6189|4|1042|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6190|4|1042|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6191|4|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6192|4|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6193|4|1046|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6194|4|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6195|4|1051|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6196|4|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6197|4|1056|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6198|4|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6199|4|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6200|4|1061|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6201|4|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6202|4|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6203|4|1065|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6204|4|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6205|4|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6206|4|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6207|4|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6208|4|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6209|4|1075|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6210|4|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6211|4|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6212|4|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6213|4|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6214|4|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6215|4|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6216|4|1088|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6217|4|1095|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6218|4|1102|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6219|4|1107|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6220|4|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6221|4|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6222|4|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6223|4|1126|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6224|4|1130|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6225|4|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6226|4|1154|Other deterministic changes|Whole body|NVL|
1007-2-4|C57BL/6 male mice 0.5 Gy exposure at 10 weeks,B6M50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|254 (254 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-4-6227|4|1231|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6228|5|132|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6229|5|325|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6230|5|357|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6231|5|387|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6232|5|399|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6233|5|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6234|5|457|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6235|5|457|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6236|5|468|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6237|5|471|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6238|5|506|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6239|5|545|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6240|5|556|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6241|5|556|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6242|5|569|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6243|5|584|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6244|5|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6245|5|604|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6246|5|605|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6247|5|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6248|5|619|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6249|5|622|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6250|5|630|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6251|5|652|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6252|5|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6253|5|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6254|5|668|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6255|5|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6256|5|679|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6257|5|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6258|5|685|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6259|5|694|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6260|5|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6261|5|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6262|5|709|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6263|5|720|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6264|5|720|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6265|5|720|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6266|5|721|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6267|5|727|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6268|5|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6269|5|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6270|5|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6271|5|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6272|5|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6273|5|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6274|5|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6275|5|758|Neoplasia malignant|Endocrine system|THARC|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6276|5|758|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6277|5|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6278|5|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6279|5|759|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6280|5|761|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6281|5|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6282|5|764|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6283|5|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6284|5|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6285|5|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6286|5|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6287|5|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6288|5|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6289|5|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6290|5|780|Neoplasia malignant|Endocrine system|THARC|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6291|5|783|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6292|5|786|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6293|5|786|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6294|5|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6295|5|787|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6296|5|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6297|5|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6298|5|790|Neoplasia malignant|Endocrine system|THARC|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6299|5|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6300|5|794|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6301|5|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6302|5|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6303|5|799|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6304|5|801|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6305|5|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6306|5|802|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6307|5|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6308|5|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6309|5|808|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6310|5|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6311|5|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6312|5|815|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6313|5|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6314|5|818|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6315|5|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6316|5|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6317|5|824|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6318|5|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6319|5|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6320|5|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6321|5|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6322|5|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6323|5|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6324|5|848|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6325|5|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6326|5|853|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6327|5|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6328|5|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6329|5|859|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6330|5|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6331|5|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6332|5|875|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6333|5|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6334|5|878|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6335|5|881|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6336|5|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6337|5|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6338|5|887|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6339|5|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6340|5|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6341|5|888|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6342|5|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6343|5|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6344|5|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6345|5|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6346|5|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6347|5|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6348|5|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6349|5|897|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6350|5|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6351|5|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6352|5|902|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6353|5|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6354|5|902|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6355|5|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6356|5|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6357|5|907|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6358|5|909|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6359|5|910|Neoplasia benign|Endocrine system|THARA|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6360|5|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6361|5|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6362|5|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6363|5|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6364|5|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6365|5|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6366|5|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6367|5|918|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6368|5|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6369|5|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6370|5|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6371|5|923|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6372|5|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6373|5|923|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6374|5|926|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6375|5|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6376|5|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6377|5|927|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6378|5|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6379|5|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6380|5|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6381|5|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6382|5|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6383|5|939|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6384|5|939|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6385|5|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6386|5|942|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6387|5|944|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6388|5|950|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6389|5|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6390|5|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6391|5|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6392|5|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6393|5|952|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6394|5|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6395|5|958|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6396|5|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6397|5|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6398|5|959|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6399|5|959|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6400|5|960|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6401|5|961|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6402|5|961|Neoplasia malignant|Endocrine system|THARC|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6403|5|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6404|5|961|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6405|5|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6406|5|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6407|5|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6408|5|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6409|5|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6410|5|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6411|5|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6412|5|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6413|5|973|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6414|5|973|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6415|5|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6416|5|974|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6417|5|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6418|5|975|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6419|5|975|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6420|5|975|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6421|5|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6422|5|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6423|5|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6424|5|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6425|5|986|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6426|5|986|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6427|5|986|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6428|5|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6429|5|989|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6430|5|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6431|5|992|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6432|5|994|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6433|5|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6434|5|996|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6435|5|998|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6436|5|1000|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6437|5|1001|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6438|5|1003|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6439|5|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6440|5|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6441|5|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6442|5|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6443|5|1014|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6444|5|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6445|5|1016|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6446|5|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6447|5|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6448|5|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6449|5|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6450|5|1024|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6451|5|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6452|5|1037|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6453|5|1039|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6454|5|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6455|5|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6456|5|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6457|5|1050|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6458|5|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6459|5|1051|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6460|5|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6461|5|1056|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6462|5|1063|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6463|5|1069|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6464|5|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6465|5|1077|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6466|5|1077|Other deterministic changes|Whole body|NVL|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6467|5|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6468|5|1081|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6469|5|1088|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6470|5|1094|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6471|5|1095|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6472|5|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6473|5|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6474|5|1126|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6475|5|1126|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6476|5|1127|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6477|5|1150|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-5|C57BL/6 female mice 1.0 Gy exposure at 10 weeks,B6F100A|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|251 (251 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-5-6478|5|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6479|6|455|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6480|6|468|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6481|6|549|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6482|6|573|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6483|6|580|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6484|6|585|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6485|6|589|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6486|6|591|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6487|6|611|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6488|6|636|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6489|6|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6490|6|658|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6491|6|661|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6492|6|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6493|6|673|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6494|6|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6495|6|682|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6496|6|699|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6497|6|706|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6498|6|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6499|6|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6500|6|715|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6501|6|715|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6502|6|722|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6503|6|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6504|6|727|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6505|6|734|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6506|6|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6507|6|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6508|6|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6509|6|751|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6510|6|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6511|6|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6512|6|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6513|6|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6514|6|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6515|6|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6516|6|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6517|6|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6518|6|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6519|6|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6520|6|787|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6521|6|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6522|6|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6523|6|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6524|6|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6525|6|799|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6526|6|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6527|6|808|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6528|6|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6529|6|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6530|6|816|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6531|6|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6532|6|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6533|6|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6534|6|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6535|6|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6536|6|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6537|6|833|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6538|6|835|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6539|6|836|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6540|6|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6541|6|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6542|6|848|Neoplasia malignant|Endocrine system|THARC|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6543|6|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6544|6|849|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6545|6|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6546|6|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6547|6|856|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6548|6|860|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6549|6|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6550|6|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6551|6|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6552|6|875|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6553|6|876|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6554|6|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6555|6|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6556|6|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6557|6|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6558|6|882|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6559|6|885|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6560|6|888|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6561|6|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6562|6|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6563|6|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6564|6|892|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6565|6|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6566|6|897|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6567|6|898|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6568|6|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6569|6|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6570|6|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6571|6|909|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6572|6|910|Neoplasia benign|Endocrine system|THARA|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6573|6|910|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6574|6|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6575|6|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6576|6|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6577|6|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6578|6|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6579|6|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6580|6|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6581|6|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6582|6|924|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6583|6|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6584|6|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6585|6|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6586|6|927|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6587|6|927|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6588|6|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6589|6|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6590|6|931|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TINTC,MPATH: 549 - carcinoma|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6591|6|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6592|6|934|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6593|6|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6594|6|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6595|6|938|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6596|6|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6597|6|940|Neoplasia benign|Endocrine system|THARA|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6598|6|941|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6599|6|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6600|6|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6601|6|941|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6602|6|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6603|6|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6604|6|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6605|6|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6606|6|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6607|6|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6608|6|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6609|6|954|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6610|6|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6611|6|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6612|6|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6613|6|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6614|6|958|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6615|6|958|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6616|6|960|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6617|6|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6618|6|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6619|6|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6620|6|961|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6621|6|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6622|6|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6623|6|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6624|6|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6625|6|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6626|6|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6627|6|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6628|6|967|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6629|6|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6630|6|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6631|6|969|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6632|6|970|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6633|6|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6634|6|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6635|6|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6636|6|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6637|6|975|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6638|6|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6639|6|976|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6640|6|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6641|6|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6642|6|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6643|6|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6644|6|980|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6645|6|980|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6646|6|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6647|6|983|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6648|6|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6649|6|984|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6650|6|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6651|6|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6652|6|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6653|6|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6654|6|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6655|6|988|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6656|6|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6657|6|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6658|6|994|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6659|6|995|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6660|6|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6661|6|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6662|6|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6663|6|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6664|6|1001|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6665|6|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6666|6|1004|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6667|6|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6668|6|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6669|6|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6670|6|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6671|6|1015|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6672|6|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6673|6|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6674|6|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6675|6|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6676|6|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6677|6|1021|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6678|6|1021|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6679|6|1022|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6680|6|1022|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6681|6|1023|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6682|6|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6683|6|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6684|6|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6685|6|1025|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6686|6|1025|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6687|6|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6688|6|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6689|6|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6690|6|1032|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6691|6|1032|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6692|6|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6693|6|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6694|6|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6695|6|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6696|6|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6697|6|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6698|6|1045|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6699|6|1045|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6700|6|1046|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6701|6|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6702|6|1049|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6703|6|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6704|6|1052|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6705|6|1055|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6706|6|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6707|6|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6708|6|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6709|6|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6710|6|1059|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6711|6|1059|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6712|6|1059|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6713|6|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6714|6|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6715|6|1066|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6716|6|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6717|6|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6718|6|1074|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6719|6|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6720|6|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6721|6|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6722|6|1081|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6723|6|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6724|6|1091|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6725|6|1093|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6726|6|1094|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6727|6|1094|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6728|6|1098|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6729|6|1102|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6730|6|1111|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6731|6|1119|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6732|6|1119|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6733|6|1119|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6734|6|1126|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6735|6|1141|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6736|6|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6737|6|1177|Other deterministic changes|Whole body|NVL|
1007-2-6|C57BL/6 male mice 1.0 Gy exposure at  10 weeks,B6M100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|260 (260 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-6-6738|6|1203|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-245|7|n/a|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-255|7|773|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6739|7|237|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6740|7|317|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6741|7|457|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6742|7|485|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6743|7|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6744|7|510|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6745|7|514|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6746|7|525|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6747|7|547|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6748|7|547|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6749|7|556|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6750|7|561|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6751|7|566|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6752|7|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6753|7|580|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6754|7|584|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6755|7|589|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6756|7|590|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6757|7|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6758|7|594|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6759|7|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6760|7|601|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6761|7|603|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6762|7|609|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6763|7|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6764|7|623|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6765|7|626|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6766|7|630|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6767|7|639|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6768|7|639|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6769|7|657|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6770|7|657|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6771|7|665|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6772|7|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6773|7|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6774|7|671|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6775|7|673|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6776|7|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6777|7|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6778|7|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6779|7|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6780|7|679|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6781|7|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6782|7|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6783|7|685|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6784|7|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6785|7|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6786|7|692|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6787|7|692|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6788|7|693|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6789|7|694|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6790|7|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6791|7|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6792|7|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6793|7|706|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6794|7|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6795|7|713|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6796|7|717|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6797|7|721|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6798|7|724|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6799|7|727|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6800|7|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6801|7|728|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6802|7|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6803|7|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6804|7|729|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6805|7|730|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6806|7|735|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6807|7|740|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6808|7|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6809|7|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6810|7|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6811|7|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6812|7|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6813|7|748|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6814|7|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6815|7|756|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6816|7|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6817|7|759|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6818|7|766|Neoplasia systemic|Haematolymphatic system|LMYL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6819|7|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6820|7|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6821|7|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6822|7|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6823|7|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6824|7|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6825|7|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6826|7|788|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6827|7|789|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6828|7|790|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6829|7|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6830|7|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6831|7|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6832|7|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6833|7|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6834|7|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6835|7|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6836|7|806|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6837|7|806|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6838|7|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6839|7|808|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6840|7|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6841|7|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6842|7|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6843|7|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6844|7|815|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6845|7|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6846|7|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6847|7|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6848|7|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6849|7|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6850|7|829|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6851|7|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6852|7|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6853|7|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6854|7|836|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6855|7|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6856|7|839|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6857|7|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6858|7|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6859|7|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6860|7|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6861|7|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6862|7|846|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6863|7|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6864|7|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6865|7|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6866|7|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6867|7|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6868|7|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6869|7|853|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6870|7|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6871|7|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6872|7|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6873|7|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6874|7|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6875|7|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6876|7|869|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6877|7|870|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6878|7|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6879|7|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6880|7|874|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6881|7|875|Neoplasia benign|Endocrine system|THARA|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6882|7|876|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6883|7|877|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6884|7|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6885|7|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6886|7|884|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6887|7|884|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6888|7|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6889|7|885|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6890|7|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6891|7|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6892|7|889|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6893|7|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6894|7|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6895|7|898|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6896|7|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6897|7|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6898|7|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6899|7|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6900|7|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6901|7|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6902|7|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6903|7|909|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6904|7|909|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6905|7|909|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6906|7|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6907|7|910|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6908|7|911|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6909|7|911|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6910|7|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6911|7|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6912|7|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6913|7|917|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6914|7|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6915|7|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6916|7|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6917|7|924|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6918|7|925|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKIDC,MPATH: 549 - carcinoma|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6919|7|925|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6920|7|930|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6921|7|930|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6922|7|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6923|7|932|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6924|7|932|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6925|7|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6926|7|937|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6927|7|940|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6928|7|940|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6929|7|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6930|7|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6931|7|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6932|7|951|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6933|7|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6934|7|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6935|7|953|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6936|7|954|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6937|7|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6938|7|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6939|7|956|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6940|7|958|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6941|7|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6942|7|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6943|7|961|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6944|7|961|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6945|7|963|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6946|7|967|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6947|7|972|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6948|7|972|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6949|7|972|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6950|7|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6951|7|975|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6952|7|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6953|7|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6954|7|986|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6955|7|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6956|7|987|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6957|7|988|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6958|7|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6959|7|990|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6960|7|993|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6961|7|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6962|7|1001|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6963|7|1006|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6964|7|1008|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6965|7|1011|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6966|7|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6967|7|1015|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6968|7|1016|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6969|7|1018|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6970|7|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6971|7|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6972|7|1024|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6973|7|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6974|7|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6975|7|1036|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6976|7|1041|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6977|7|1043|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6978|7|1047|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6979|7|1053|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6980|7|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6981|7|1058|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6982|7|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6983|7|1085|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6984|7|1088|Other deterministic changes|Whole body|NVL|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6985|7|1096|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6986|7|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6987|7|1112|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6988|7|1112|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6989|7|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6990|7|1136|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-7|C57BL/6 female mice 2.0 Gy exposure at 10 weeks,B6F200A|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|253 (255 in ERA)|Mouse|Mouse, C57BL/6Bd|Female|need def 11|Survival, carcinogenesis|1007-2-7-6991|7|1148|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6992|8|195|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6993|8|224|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6994|8|269|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6995|8|353|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6996|8|394|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6997|8|447|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6998|8|450|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-6999|8|461|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7000|8|463|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7001|8|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7002|8|524|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7003|8|554|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7004|8|556|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7005|8|556|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7006|8|566|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7007|8|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7008|8|590|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7009|8|591|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7010|8|610|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7011|8|619|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7012|8|629|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7013|8|663|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7014|8|666|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7015|8|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7016|8|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7017|8|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7018|8|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7019|8|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7020|8|695|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7021|8|699|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7022|8|699|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7023|8|699|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7024|8|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7025|8|713|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7026|8|714|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7027|8|714|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7028|8|723|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7029|8|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7030|8|734|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7031|8|735|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7032|8|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7033|8|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7034|8|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7035|8|741|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7036|8|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7037|8|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7038|8|762|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7039|8|762|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7040|8|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7041|8|764|Neoplasia malignant|Endocrine system|THARC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7042|8|766|Neoplasia malignant|Endocrine system|THARC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7043|8|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7044|8|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7045|8|783|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7046|8|787|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7047|8|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7048|8|789|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7049|8|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7050|8|792|Neoplasia malignant|Endocrine system|THARC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7051|8|796|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7052|8|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7053|8|801|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7054|8|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7055|8|805|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7056|8|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7057|8|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7058|8|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7059|8|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7060|8|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7061|8|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7062|8|818|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7063|8|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7064|8|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7065|8|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7066|8|825|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7067|8|832|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7068|8|836|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7069|8|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7070|8|841|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7071|8|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7072|8|842|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7073|8|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7074|8|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7075|8|849|Neoplasia malignant|Endocrine system|THARC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7076|8|853|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7077|8|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7078|8|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7079|8|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7080|8|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7081|8|858|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7082|8|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7083|8|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7084|8|861|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7085|8|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7086|8|867|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7087|8|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7088|8|872|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7089|8|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7090|8|874|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7091|8|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7092|8|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7093|8|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7094|8|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7095|8|879|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7096|8|879|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7097|8|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7098|8|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7099|8|883|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7100|8|883|Neoplasia malignant|Endocrine system|THARC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7101|8|883|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7102|8|885|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7103|8|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7104|8|888|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7105|8|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7106|8|894|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7107|8|895|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7108|8|895|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7109|8|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7110|8|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7111|8|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7112|8|907|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7113|8|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7114|8|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7115|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7116|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7117|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7118|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7119|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7120|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7121|8|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7122|8|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7123|8|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7124|8|919|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7125|8|919|Neoplasia systemic|Haematolymphatic system|LMYL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7126|8|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7127|8|923|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7128|8|923|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7129|8|924|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7130|8|926|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7131|8|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7132|8|930|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7133|8|930|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7134|8|932|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7135|8|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7136|8|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7137|8|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7138|8|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7139|8|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7140|8|941|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7141|8|942|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7142|8|944|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7143|8|944|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7144|8|947|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7145|8|947|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7146|8|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7147|8|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7148|8|952|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7149|8|953|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7150|8|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7151|8|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7152|8|955|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7153|8|958|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7154|8|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7155|8|960|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7156|8|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7157|8|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7158|8|961|Neoplasia benign|Endocrine system|THARA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7159|8|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7160|8|962|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7161|8|965|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7162|8|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7163|8|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7164|8|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7165|8|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7166|8|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7167|8|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7168|8|974|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7169|8|975|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7170|8|976|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7171|8|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7172|8|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7173|8|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7174|8|980|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7175|8|981|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7176|8|986|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7177|8|987|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7178|8|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7179|8|988|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7180|8|989|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7181|8|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7182|8|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7183|8|993|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7184|8|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7185|8|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7186|8|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7187|8|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7188|8|1003|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7189|8|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7190|8|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7191|8|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7192|8|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7193|8|1009|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7194|8|1011|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7195|8|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7196|8|1015|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7197|8|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7198|8|1017|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7199|8|1021|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7200|8|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7201|8|1022|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7202|8|1023|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7203|8|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7204|8|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7205|8|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7206|8|1032|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7207|8|1032|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7208|8|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7209|8|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7210|8|1037|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7211|8|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7212|8|1044|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7213|8|1045|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7214|8|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7215|8|1051|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7216|8|1052|Neoplasia malignant|Endocrine system|THARC|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7217|8|1054|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7218|8|1056|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7219|8|1056|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7220|8|1058|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7221|8|1060|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7222|8|1063|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7223|8|1063|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7224|8|1063|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7225|8|1064|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7226|8|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7227|8|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7228|8|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7229|8|1070|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7230|8|1078|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7231|8|1079|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7232|8|1087|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7233|8|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7234|8|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7235|8|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7236|8|1105|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7237|8|1112|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7238|8|1112|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7239|8|1113|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7240|8|1113|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7241|8|1120|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7242|8|1126|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7243|8|1144|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7244|8|1149|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7245|8|1150|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7246|8|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7247|8|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7248|8|1186|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7249|8|1210|Other deterministic changes|Whole body|NVL|
1007-2-8|C57BL/6 male mice 2.0 Gy exposure at 10 weeks,B6M200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|259 (259 in ERA)|Mouse|Mouse, C57BL/6Bd|Male|need def 11|Survival, carcinogenesis|1007-2-8-7250|8|1217|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7251|9|223|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7252|9|360|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7253|9|381|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7254|9|386|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TBLDC,MPATH: 549 - carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7255|9|401|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7256|9|419|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|TPANC,MPATH: 268 - adenocarcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7257|9|436|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7258|9|450|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7259|9|457|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7260|9|457|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7261|9|468|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7262|9|471|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7263|9|482|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7264|9|493|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7265|9|498|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7266|9|499|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7267|9|500|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7268|9|506|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7269|9|521|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7270|9|528|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7271|9|528|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7272|9|534|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7273|9|535|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7274|9|536|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7275|9|546|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7276|9|546|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7277|9|547|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7278|9|549|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7279|9|554|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7280|9|554|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7281|9|559|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7282|9|559|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7283|9|563|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7284|9|563|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7285|9|566|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7286|9|566|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7287|9|566|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7288|9|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LSAR,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7289|9|568|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7290|9|573|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7291|9|576|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7292|9|580|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7293|9|582|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7294|9|582|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7295|9|584|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7296|9|584|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7297|9|589|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7298|9|590|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7299|9|591|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7300|9|591|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7301|9|597|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7302|9|598|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7303|9|598|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7304|9|600|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7305|9|602|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7306|9|602|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7307|9|602|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7308|9|603|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7309|9|605|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7310|9|608|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7311|9|610|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7312|9|611|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7313|9|612|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7314|9|615|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7315|9|615|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7316|9|619|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7317|9|629|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LTHY,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7318|9|630|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7319|9|630|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7320|9|630|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7321|9|633|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7322|9|633|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7323|9|638|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7324|9|643|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7325|9|647|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7326|9|649|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7327|9|649|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7328|9|652|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7329|9|653|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7330|9|653|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7331|9|654|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7332|9|654|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7333|9|657|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7334|9|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7335|9|663|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7336|9|664|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7337|9|667|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7338|9|668|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7339|9|671|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7340|9|672|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7341|9|672|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7342|9|674|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7343|9|675|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7344|9|678|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7345|9|678|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7346|9|679|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7347|9|679|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7348|9|682|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7349|9|682|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7350|9|685|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7351|9|685|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7352|9|686|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7353|9|687|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7354|9|687|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7355|9|687|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7356|9|689|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7357|9|689|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7358|9|692|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7359|9|692|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7360|9|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7361|9|693|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7362|9|694|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7363|9|694|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7364|9|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7365|9|695|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7366|9|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7367|9|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7368|9|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7369|9|698|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7370|9|698|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7371|9|699|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7372|9|708|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7373|9|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7374|9|710|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7375|9|710|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7376|9|713|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7377|9|713|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7378|9|713|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7379|9|713|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7380|9|713|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7381|9|714|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7382|9|716|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7383|9|716|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7384|9|717|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7385|9|720|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7386|9|720|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7387|9|721|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7388|9|721|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7389|9|722|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7390|9|723|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7391|9|723|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7392|9|723|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7393|9|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7394|9|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7395|9|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7396|9|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7397|9|724|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7398|9|724|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7399|9|727|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7400|9|727|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7401|9|728|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7402|9|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7403|9|730|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7404|9|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7405|9|731|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7406|9|731|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7407|9|735|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7408|9|735|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7409|9|736|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7410|9|737|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7411|9|737|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7412|9|738|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7413|9|741|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7414|9|741|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7415|9|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7416|9|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7417|9|741|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7418|9|742|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7419|9|744|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7420|9|744|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7421|9|745|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7422|9|745|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7423|9|745|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7424|9|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7425|9|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7426|9|749|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7427|9|749|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7428|9|750|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7429|9|750|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7430|9|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7431|9|752|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7432|9|756|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7433|9|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7434|9|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7435|9|758|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7436|9|758|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7437|9|759|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7438|9|759|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7439|9|763|Neoplasia benign|Endocrine system|THARA|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7440|9|763|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7441|9|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7442|9|765|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7443|9|769|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7444|9|769|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7445|9|769|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7446|9|769|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7447|9|769|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7448|9|770|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7449|9|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7450|9|771|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7451|9|771|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7452|9|771|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7453|9|771|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7454|9|772|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7455|9|772|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7456|9|772|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7457|9|773|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7458|9|773|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7459|9|773|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7460|9|773|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7461|9|775|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7462|9|776|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7463|9|777|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7464|9|777|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7465|9|778|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7466|9|778|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7467|9|779|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7468|9|779|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7469|9|779|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7470|9|779|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7471|9|779|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7472|9|779|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7473|9|780|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7474|9|781|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7475|9|783|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7476|9|783|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7477|9|783|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7478|9|783|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7479|9|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7480|9|783|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7481|9|785|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7482|9|785|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7483|9|785|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7484|9|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7485|9|785|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7486|9|786|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7487|9|787|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7488|9|787|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7489|9|790|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7490|9|790|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7491|9|790|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7492|9|790|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7493|9|791|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7494|9|791|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7495|9|791|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7496|9|792|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7497|9|792|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7498|9|792|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7499|9|792|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7500|9|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7501|9|798|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7502|9|798|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7503|9|799|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7504|9|799|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7505|9|799|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7506|9|799|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7507|9|800|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7508|9|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7509|9|800|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7510|9|800|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7511|9|800|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7512|9|800|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7513|9|800|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7514|9|800|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7515|9|801|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7516|9|802|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7517|9|804|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7518|9|804|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7519|9|804|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7520|9|804|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7521|9|805|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7522|9|805|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7523|9|807|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7524|9|808|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7525|9|808|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7526|9|808|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7527|9|808|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7528|9|808|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7529|9|808|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7530|9|811|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7531|9|811|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7532|9|811|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7533|9|811|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7534|9|811|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7535|9|812|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7536|9|812|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7537|9|812|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7538|9|812|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7539|9|813|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7540|9|813|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7541|9|813|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7542|9|813|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7543|9|813|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7544|9|814|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7545|9|814|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7546|9|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7547|9|815|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7548|9|815|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7549|9|815|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7550|9|818|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7551|9|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7552|9|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7553|9|818|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7554|9|819|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7555|9|819|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7556|9|819|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7557|9|820|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7558|9|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7559|9|821|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7560|9|821|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7561|9|822|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7562|9|824|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7563|9|824|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7564|9|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7565|9|825|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7566|9|825|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7567|9|825|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7568|9|825|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7569|9|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7570|9|825|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7571|9|826|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7572|9|826|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7573|9|827|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7574|9|827|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7575|9|828|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7576|9|828|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7577|9|829|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7578|9|829|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7579|9|829|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7580|9|830|Neoplasia malignant|Endocrine system|THARC|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7581|9|832|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7582|9|832|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7583|9|832|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7584|9|832|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7585|9|832|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7586|9|832|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7587|9|832|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7588|9|833|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7589|9|833|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7590|9|833|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7591|9|834|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7592|9|834|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7593|9|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7594|9|836|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7595|9|836|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7596|9|839|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7597|9|839|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7598|9|840|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7599|9|841|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7600|9|841|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7601|9|842|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7602|9|842|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7603|9|843|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7604|9|843|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7605|9|843|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7606|9|844|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TINT,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7607|9|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7608|9|847|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7609|9|850|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7610|9|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7611|9|850|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7612|9|850|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7613|9|851|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7614|9|853|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7615|9|853|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7616|9|853|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7617|9|853|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7618|9|854|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7619|9|855|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7620|9|856|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7621|9|856|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7622|9|857|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7623|9|857|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7624|9|859|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7625|9|860|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7626|9|860|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7627|9|861|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7628|9|861|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7629|9|861|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7630|9|862|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7631|9|863|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7632|9|864|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7633|9|864|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7634|9|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7635|9|867|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7636|9|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7637|9|867|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7638|9|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7639|9|867|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7640|9|868|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7641|9|869|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7642|9|869|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7643|9|869|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7644|9|870|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7645|9|871|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7646|9|871|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7647|9|871|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7648|9|872|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7649|9|875|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7650|9|875|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7651|9|876|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7652|9|876|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7653|9|876|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7654|9|876|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7655|9|878|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7656|9|881|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7657|9|884|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7658|9|884|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7659|9|884|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7660|9|887|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7661|9|890|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7662|9|893|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7663|9|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7664|9|895|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7665|9|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7666|9|896|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7667|9|897|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7668|9|897|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7669|9|902|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7670|9|903|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7671|9|904|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7672|9|906|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7673|9|906|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7674|9|906|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7675|9|907|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7676|9|909|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7677|9|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7678|9|910|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7679|9|912|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7680|9|912|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7681|9|912|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7682|9|912|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7683|9|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7684|9|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7685|9|916|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7686|9|918|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7687|9|919|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7688|9|920|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7689|9|923|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7690|9|923|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7691|9|924|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7692|9|924|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7693|9|924|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7694|9|925|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7695|9|926|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7696|9|926|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7697|9|927|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7698|9|927|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7699|9|927|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7700|9|929|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7701|9|937|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7702|9|937|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7703|9|937|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7704|9|939|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7705|9|941|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7706|9|944|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7707|9|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7708|9|945|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7709|9|947|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7710|9|947|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7711|9|948|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7712|9|949|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7713|9|953|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7714|9|955|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7715|9|955|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7716|9|956|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7717|9|958|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7718|9|958|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7719|9|961|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7720|9|965|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7721|9|965|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7722|9|965|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7723|9|969|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7724|9|972|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7725|9|973|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7726|9|974|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7727|9|979|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7728|9|981|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7729|9|986|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7730|9|986|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7731|9|986|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7732|9|993|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7733|9|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7734|9|997|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7735|9|997|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7736|9|1000|Neoplasia benign|Endocrine system|THARA|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7737|9|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7738|9|1010|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7739|9|1011|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7740|9|1015|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7741|9|1015|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7742|9|1016|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7743|9|1018|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7744|9|1028|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7745|9|1028|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7746|9|1030|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7747|9|1032|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7748|9|1034|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7749|9|1036|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7750|9|1044|Other deterministic changes|Whole body|NVL|
1007-2-9|C3Hf/Bd female control mice,C3FCONT|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|501 (501 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|Survival, carcinogenesis|1007-2-9-7751|9|1046|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7752|10|146|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7753|10|169|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7754|10|232|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7755|10|286|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7756|10|359|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7757|10|398|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7758|10|405|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7759|10|420|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7760|10|427|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7761|10|429|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7762|10|433|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7763|10|468|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7764|10|470|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7765|10|477|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7766|10|477|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7767|10|483|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7768|10|485|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7769|10|486|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7770|10|492|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7771|10|498|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7772|10|499|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7773|10|503|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7774|10|503|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7775|10|513|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7776|10|513|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7777|10|518|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7778|10|520|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7779|10|524|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7780|10|524|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7781|10|531|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7782|10|531|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7783|10|533|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7784|10|538|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7785|10|545|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7786|10|545|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7787|10|545|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7788|10|546|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7789|10|548|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7790|10|549|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7791|10|549|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7792|10|555|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7793|10|557|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7794|10|559|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7795|10|566|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7796|10|567|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7797|10|568|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7798|10|570|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7799|10|573|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7800|10|573|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7801|10|574|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7802|10|574|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7803|10|575|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7804|10|580|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7805|10|580|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7806|10|580|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7807|10|580|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7808|10|583|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7809|10|583|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7810|10|583|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7811|10|587|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7812|10|587|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7813|10|588|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7814|10|589|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7815|10|589|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7816|10|590|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7817|10|591|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7818|10|591|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7819|10|594|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7820|10|598|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7821|10|599|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7822|10|601|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7823|10|601|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7824|10|601|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7825|10|603|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7826|10|603|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7827|10|604|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7828|10|604|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7829|10|608|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7830|10|608|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7831|10|608|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7832|10|609|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7833|10|610|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7834|10|612|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7835|10|615|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7836|10|615|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7837|10|616|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7838|10|616|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7839|10|618|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7840|10|619|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7841|10|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7842|10|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7843|10|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7844|10|624|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7845|10|624|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7846|10|626|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7847|10|629|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7848|10|629|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7849|10|629|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7850|10|629|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7851|10|631|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7852|10|631|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7853|10|633|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7854|10|633|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7855|10|633|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7856|10|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7857|10|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7858|10|640|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7859|10|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7860|10|643|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7861|10|643|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7862|10|644|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7863|10|646|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7864|10|650|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7865|10|650|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7866|10|650|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7867|10|651|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7868|10|652|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7869|10|653|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7870|10|654|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7871|10|654|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7872|10|654|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7873|10|655|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7874|10|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7875|10|658|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7876|10|658|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7877|10|660|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7878|10|661|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7879|10|662|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7880|10|663|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7881|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7882|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7883|10|664|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7884|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7885|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7886|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7887|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7888|10|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7889|10|664|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7890|10|665|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7891|10|667|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7892|10|667|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7893|10|671|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7894|10|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7895|10|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7896|10|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7897|10|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7898|10|672|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7899|10|672|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7900|10|673|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7901|10|674|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7902|10|674|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7903|10|676|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7904|10|678|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7905|10|678|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7906|10|678|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7907|10|678|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7908|10|679|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7909|10|679|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7910|10|679|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7911|10|681|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7912|10|681|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7913|10|684|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7914|10|685|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7915|10|685|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7916|10|685|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7917|10|685|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7918|10|686|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7919|10|687|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7920|10|687|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7921|10|687|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7922|10|688|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7923|10|688|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7924|10|689|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7925|10|689|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7926|10|689|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7927|10|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7928|10|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7929|10|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7930|10|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7931|10|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7932|10|694|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7933|10|698|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7934|10|699|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7935|10|700|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7936|10|700|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7937|10|701|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7938|10|701|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7939|10|701|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7940|10|702|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7941|10|706|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7942|10|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7943|10|706|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7944|10|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7945|10|707|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7946|10|707|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7947|10|707|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7948|10|707|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7949|10|708|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7950|10|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7951|10|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7952|10|712|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7953|10|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7954|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7955|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7956|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7957|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7958|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7959|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7960|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7961|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7962|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7963|10|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7964|10|714|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7965|10|714|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7966|10|715|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7967|10|715|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7968|10|716|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7969|10|716|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7970|10|717|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7971|10|718|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7972|10|720|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7973|10|721|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7974|10|722|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7975|10|722|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7976|10|722|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7977|10|726|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7978|10|727|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7979|10|727|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7980|10|727|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7981|10|728|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7982|10|729|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7983|10|729|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7984|10|730|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7985|10|730|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7986|10|731|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7987|10|734|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7988|10|735|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7989|10|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7990|10|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7991|10|736|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7992|10|738|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7993|10|738|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7994|10|740|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7995|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7996|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7997|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7998|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-7999|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8000|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8001|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8002|10|741|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8003|10|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8004|10|743|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8005|10|743|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8006|10|743|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8007|10|744|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8008|10|744|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8009|10|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8010|10|748|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8011|10|748|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8012|10|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8013|10|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8014|10|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8015|10|749|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8016|10|749|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8017|10|749|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8018|10|749|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8019|10|749|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8020|10|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8021|10|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8022|10|750|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8023|10|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8024|10|751|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8025|10|752|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8026|10|752|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8027|10|754|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8028|10|754|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8029|10|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8030|10|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8031|10|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8032|10|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8033|10|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8034|10|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8035|10|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8036|10|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8037|10|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8038|10|757|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8039|10|759|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8040|10|760|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8041|10|761|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8042|10|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8043|10|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8044|10|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8045|10|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8046|10|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8047|10|764|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8048|10|764|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8049|10|765|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8050|10|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8051|10|769|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8052|10|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8053|10|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8054|10|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8055|10|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8056|10|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8057|10|772|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8058|10|772|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8059|10|772|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8060|10|775|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8061|10|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8062|10|776|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8063|10|776|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8064|10|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8065|10|777|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8066|10|777|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8067|10|778|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8068|10|779|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8069|10|779|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8070|10|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8071|10|781|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8072|10|783|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8073|10|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8074|10|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8075|10|783|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8076|10|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8077|10|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8078|10|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8079|10|786|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8080|10|786|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8081|10|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8082|10|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8083|10|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8084|10|791|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8085|10|791|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8086|10|791|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8087|10|792|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8088|10|792|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8089|10|792|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8090|10|793|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8091|10|793|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8092|10|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8093|10|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8094|10|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8095|10|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8096|10|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8097|10|799|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8098|10|799|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8099|10|801|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8100|10|801|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8101|10|803|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8102|10|803|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8103|10|804|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8104|10|804|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8105|10|804|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8106|10|804|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8107|10|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8108|10|805|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8109|10|806|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8110|10|806|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8111|10|806|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8112|10|807|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8113|10|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8114|10|808|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8115|10|808|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8116|10|808|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8117|10|808|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8118|10|809|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8119|10|811|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8120|10|811|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8121|10|811|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8122|10|811|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8123|10|812|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8124|10|812|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8125|10|813|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8126|10|814|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8127|10|815|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8128|10|815|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8129|10|815|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8130|10|817|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8131|10|817|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8132|10|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8133|10|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8134|10|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8135|10|819|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8136|10|819|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8137|10|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8138|10|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8139|10|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8140|10|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8141|10|822|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8142|10|822|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8143|10|823|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8144|10|825|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8145|10|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8146|10|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8147|10|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8148|10|826|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8149|10|827|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8150|10|828|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8151|10|828|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8152|10|828|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8153|10|832|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8154|10|832|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8155|10|832|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8156|10|833|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8157|10|834|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8158|10|836|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8159|10|839|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8160|10|839|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8161|10|839|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8162|10|839|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8163|10|840|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8164|10|841|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8165|10|843|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8166|10|844|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8167|10|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8168|10|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8169|10|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8170|10|847|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8171|10|847|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8172|10|849|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8173|10|849|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8174|10|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8175|10|850|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8176|10|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8177|10|850|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8178|10|851|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8179|10|852|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8180|10|854|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8181|10|855|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8182|10|855|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8183|10|855|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8184|10|856|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8185|10|857|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8186|10|858|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8187|10|859|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8188|10|860|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8189|10|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8190|10|860|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8191|10|860|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8192|10|863|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8193|10|864|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8194|10|867|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8195|10|867|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8196|10|873|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8197|10|874|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8198|10|876|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8199|10|877|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8200|10|878|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8201|10|878|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8202|10|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8203|10|883|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8204|10|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8205|10|884|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8206|10|885|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8207|10|885|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8208|10|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8209|10|886|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8210|10|889|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8211|10|891|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8212|10|892|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8213|10|895|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8214|10|899|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8215|10|899|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8216|10|899|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8217|10|900|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8218|10|905|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8219|10|907|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8220|10|907|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8221|10|911|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8222|10|918|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8223|10|922|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8224|10|927|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8225|10|934|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8226|10|939|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8227|10|939|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8228|10|942|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8229|10|942|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8230|10|945|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8231|10|950|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8232|10|952|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8233|10|953|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8234|10|965|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8235|10|965|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8236|10|966|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8237|10|968|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8238|10|969|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8239|10|975|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8240|10|976|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8241|10|977|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8242|10|986|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8243|10|986|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8244|10|993|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8245|10|994|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8246|10|1003|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8247|10|1004|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8248|10|1010|Other deterministic changes|Whole body|NVL|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8249|10|1017|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8250|10|1017|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8251|10|1026|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8252|10|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-10|C3Hf/Bd male control mice,C3MCONTB|1|70|gamma-rays Cs-137|0|grays|External exposure|Single exposure|502 (502 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-10-8253|10|1053|Other deterministic changes|Whole body|NVL|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-46|11|n/a|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-203|11|n/a|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8254|11|398|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8255|11|400|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8256|11|409|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8257|11|436|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8258|11|454|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8259|11|492|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8260|11|506|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8261|11|510|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8262|11|531|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8263|11|532|Other deterministic changes|Whole body|NVL|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8264|11|541|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8265|11|554|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8266|11|560|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8267|11|562|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8268|11|563|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8269|11|563|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8270|11|563|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8271|11|569|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8272|11|575|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8273|11|580|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8274|11|582|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8275|11|583|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8276|11|584|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8277|11|584|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8278|11|584|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8279|11|584|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8280|11|587|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8281|11|589|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8282|11|590|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8283|11|591|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8284|11|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8285|11|591|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8286|11|591|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8287|11|591|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8288|11|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8289|11|597|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8290|11|601|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8291|11|602|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8292|11|603|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8293|11|605|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8294|11|605|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8295|11|608|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8296|11|609|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8297|11|609|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8298|11|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8299|11|614|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8300|11|629|Other deterministic changes|Whole body|NVL|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8301|11|629|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8302|11|630|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8303|11|632|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8304|11|632|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8305|11|637|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8306|11|637|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8307|11|639|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8308|11|639|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8309|11|643|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8310|11|644|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8311|11|646|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8312|11|647|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8313|11|647|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8314|11|647|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8315|11|650|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8316|11|650|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8317|11|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8318|11|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8319|11|664|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8320|11|664|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8321|11|665|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8322|11|666|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8323|11|666|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8324|11|667|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8325|11|668|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8326|11|668|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8327|11|671|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8328|11|673|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8329|11|673|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8330|11|678|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8331|11|678|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8332|11|678|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8333|11|680|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8334|11|681|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8335|11|685|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8336|11|686|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8337|11|687|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8338|11|687|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8339|11|687|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8340|11|688|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8341|11|689|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8342|11|694|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8343|11|694|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8344|11|694|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8345|11|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8346|11|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8347|11|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8348|11|703|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8349|11|703|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8350|11|706|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8351|11|706|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8352|11|706|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8353|11|709|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8354|11|713|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8355|11|713|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8356|11|715|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8357|11|715|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8358|11|716|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8359|11|716|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8360|11|717|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8361|11|717|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8362|11|717|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8363|11|723|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8364|11|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8365|11|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8366|11|727|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8367|11|728|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8368|11|728|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8369|11|729|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8370|11|730|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8371|11|730|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8372|11|730|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8373|11|731|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8374|11|731|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8375|11|734|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8376|11|734|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8377|11|735|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8378|11|737|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8379|11|737|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8380|11|737|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8381|11|738|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8382|11|738|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8383|11|741|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8384|11|741|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8385|11|741|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8386|11|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8387|11|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8388|11|742|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8389|11|742|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8390|11|743|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8391|11|745|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8392|11|747|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8393|11|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8394|11|749|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8395|11|750|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8396|11|751|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8397|11|756|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8398|11|756|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8399|11|758|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8400|11|759|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8401|11|761|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8402|11|761|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8403|11|765|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8404|11|765|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8405|11|766|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8406|11|769|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8407|11|770|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8408|11|771|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8409|11|772|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8410|11|773|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8411|11|773|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8412|11|775|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8413|11|777|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8414|11|777|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8415|11|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8416|11|780|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8417|11|780|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8418|11|782|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8419|11|783|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8420|11|787|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8421|11|789|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8422|11|790|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8423|11|791|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8424|11|792|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8425|11|793|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8426|11|797|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8427|11|798|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8428|11|798|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8429|11|799|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8430|11|799|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8431|11|799|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8432|11|799|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8433|11|800|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8434|11|801|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8435|11|801|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8436|11|804|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8437|11|806|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8438|11|811|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8439|11|811|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8440|11|811|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8441|11|811|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8442|11|813|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8443|11|813|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8444|11|814|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8445|11|814|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8446|11|815|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8447|11|815|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8448|11|818|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8449|11|819|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8450|11|820|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8451|11|820|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8452|11|820|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8453|11|821|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8454|11|822|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8455|11|822|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8456|11|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8457|11|827|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8458|11|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8459|11|828|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8460|11|828|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8461|11|829|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8462|11|829|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8463|11|829|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8464|11|832|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8465|11|833|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8466|11|834|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8467|11|835|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8468|11|838|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8469|11|840|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8470|11|841|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8471|11|842|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8472|11|844|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8473|11|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8474|11|846|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8475|11|847|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8476|11|847|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8477|11|847|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8478|11|849|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8479|11|856|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8480|11|861|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8481|11|862|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8482|11|862|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8483|11|863|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8484|11|877|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8485|11|878|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8486|11|878|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8487|11|880|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8488|11|883|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8489|11|884|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8490|11|884|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8491|11|886|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8492|11|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8493|11|893|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8494|11|895|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8495|11|905|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8496|11|912|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8497|11|916|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8498|11|937|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8499|11|941|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8500|11|960|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8501|11|961|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-11|C3Hf/Bd female mice 0.5 Gy exposure at 10 weeks,C3F50|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|249 (251 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-11-8502|11|986|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8503|12|269|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8504|12|321|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8505|12|426|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8506|12|435|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8507|12|449|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8508|12|454|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8509|12|457|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8510|12|457|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8511|12|460|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8512|12|461|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8513|12|464|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8514|12|468|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8515|12|475|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8516|12|476|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8517|12|486|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8518|12|486|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8519|12|492|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8520|12|505|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8521|12|513|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8522|12|515|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8523|12|517|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8524|12|518|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8525|12|524|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8526|12|527|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8527|12|532|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8528|12|548|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8529|12|552|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8530|12|552|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8531|12|554|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|TPANA,MPATH: 270 - adenoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8532|12|555|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8533|12|565|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8534|12|573|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8535|12|573|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8536|12|573|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8537|12|573|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8538|12|580|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8539|12|589|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8540|12|590|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8541|12|594|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8542|12|595|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8543|12|602|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8544|12|608|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8545|12|608|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8546|12|609|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8547|12|610|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8548|12|610|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8549|12|611|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8550|12|615|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8551|12|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8552|12|622|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8553|12|623|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8554|12|628|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8555|12|633|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8556|12|634|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8557|12|636|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8558|12|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8559|12|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8560|12|638|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8561|12|642|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8562|12|643|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8563|12|643|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8564|12|645|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8565|12|647|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8566|12|650|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8567|12|652|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8568|12|652|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8569|12|654|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8570|12|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8571|12|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8572|12|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8573|12|658|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8574|12|658|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8575|12|659|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8576|12|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8577|12|664|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8578|12|665|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8579|12|666|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8580|12|666|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8581|12|667|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8582|12|668|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8583|12|671|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8584|12|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8585|12|671|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8586|12|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8587|12|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8588|12|672|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8589|12|674|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8590|12|674|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8591|12|675|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8592|12|675|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8593|12|675|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8594|12|679|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8595|12|685|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8596|12|688|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8597|12|688|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8598|12|689|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8599|12|689|Neoplasia malignant|Endocrine system|THARC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8600|12|690|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8601|12|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8602|12|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8603|12|696|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8604|12|699|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8605|12|702|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8606|12|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8607|12|705|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8608|12|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8609|12|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8610|12|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8611|12|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8612|12|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8613|12|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8614|12|707|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8615|12|707|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8616|12|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8617|12|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8618|12|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8619|12|710|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8620|12|717|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8621|12|717|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8622|12|717|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8623|12|720|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8624|12|722|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8625|12|731|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8626|12|731|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8627|12|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8628|12|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8629|12|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8630|12|735|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8631|12|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8632|12|740|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8633|12|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8634|12|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8635|12|742|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8636|12|742|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8637|12|743|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8638|12|743|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8639|12|744|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8640|12|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8641|12|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8642|12|749|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8643|12|749|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8644|12|749|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8645|12|751|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8646|12|753|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8647|12|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8648|12|755|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8649|12|757|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8650|12|758|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8651|12|759|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8652|12|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8653|12|763|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8654|12|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8655|12|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8656|12|765|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8657|12|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8658|12|766|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8659|12|766|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8660|12|766|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8661|12|766|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8662|12|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8663|12|770|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8664|12|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8665|12|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8666|12|777|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8667|12|778|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8668|12|780|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8669|12|782|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8670|12|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8671|12|786|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8672|12|786|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8673|12|789|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8674|12|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8675|12|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8676|12|791|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8677|12|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8678|12|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8679|12|795|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8680|12|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8681|12|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8682|12|797|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8683|12|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8684|12|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8685|12|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8686|12|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8687|12|801|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8688|12|801|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8689|12|804|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8690|12|804|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8691|12|804|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8692|12|805|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8693|12|806|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8694|12|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8695|12|811|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8696|12|811|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8697|12|814|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8698|12|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8699|12|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8700|12|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8701|12|822|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8702|12|822|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8703|12|822|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8704|12|826|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8705|12|827|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8706|12|828|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8707|12|829|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8708|12|830|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8709|12|832|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8710|12|832|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8711|12|835|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8712|12|836|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8713|12|839|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8714|12|840|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8715|12|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8716|12|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8717|12|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8718|12|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8719|12|849|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8720|12|853|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8721|12|855|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8722|12|860|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8723|12|863|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8724|12|864|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8725|12|867|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8726|12|868|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8727|12|868|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8728|12|874|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8729|12|880|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8730|12|880|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8731|12|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8732|12|885|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8733|12|889|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8734|12|892|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8735|12|894|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8736|12|895|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8737|12|913|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8738|12|916|Other deterministic changes|Whole body|NVL|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8739|12|917|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8740|12|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8741|12|933|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8742|12|933|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8743|12|938|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8744|12|946|Neoplasia malignant|Endocrine system|THARC|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8745|12|949|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-12|C3Hf/Bd male mice 0.5 Gy exposure at 10 weeks,C3M50B|1|70|gamma-rays Cs-137|0.5|grays|External exposure|Single exposure|244 (244 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-12-8746|12|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8747|13|269|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8748|13|365|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8749|13|402|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8750|13|402|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8751|13|416|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8752|13|426|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8753|13|448|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8754|13|452|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8755|13|454|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8756|13|458|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8757|13|465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8758|13|465|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8759|13|468|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8760|13|476|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8761|13|479|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8762|13|479|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8763|13|493|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8764|13|498|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8765|13|501|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8766|13|504|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8767|13|507|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8768|13|507|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8769|13|510|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8770|13|518|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8771|13|519|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8772|13|521|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8773|13|521|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8774|13|521|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8775|13|524|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8776|13|545|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8777|13|549|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8778|13|555|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8779|13|562|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8780|13|563|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8781|13|566|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8782|13|566|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8783|13|569|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8784|13|573|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8785|13|573|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8786|13|573|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8787|13|579|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8788|13|583|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8789|13|587|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8790|13|590|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8791|13|591|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8792|13|594|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8793|13|597|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8794|13|598|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8795|13|601|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8796|13|601|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8797|13|602|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8798|13|604|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8799|13|604|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8800|13|605|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8801|13|605|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8802|13|608|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8803|13|608|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8804|13|609|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8805|13|609|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8806|13|611|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8807|13|612|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8808|13|612|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8809|13|615|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8810|13|616|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8811|13|616|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8812|13|616|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8813|13|617|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8814|13|618|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8815|13|618|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8816|13|619|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8817|13|624|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8818|13|626|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8819|13|629|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8820|13|630|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8821|13|632|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8822|13|632|Neoplasia malignant|Endocrine system|THARC|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8823|13|637|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8824|13|638|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8825|13|640|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8826|13|645|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8827|13|647|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8828|13|647|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8829|13|650|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8830|13|650|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8831|13|654|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8832|13|657|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8833|13|658|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8834|13|659|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8835|13|659|Neoplasia malignant|Endocrine system|THARC|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8836|13|659|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8837|13|661|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8838|13|661|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8839|13|663|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8840|13|665|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8841|13|665|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8842|13|667|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8843|13|668|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8844|13|668|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8845|13|671|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8846|13|671|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8847|13|672|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8848|13|673|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8849|13|673|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8850|13|674|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8851|13|675|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8852|13|680|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8853|13|681|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8854|13|681|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8855|13|681|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8856|13|682|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8857|13|682|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8858|13|688|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8859|13|689|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8860|13|691|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8861|13|692|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8862|13|692|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8863|13|693|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8864|13|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8865|13|693|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8866|13|693|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8867|13|699|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8868|13|699|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8869|13|702|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8870|13|702|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8871|13|703|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8872|13|705|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8873|13|706|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8874|13|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8875|13|707|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8876|13|707|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8877|13|708|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8878|13|708|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8879|13|709|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8880|13|710|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8881|13|710|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8882|13|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8883|13|716|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8884|13|717|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8885|13|723|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8886|13|724|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8887|13|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8888|13|728|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8889|13|728|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8890|13|731|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8891|13|731|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8892|13|734|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8893|13|735|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8894|13|735|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8895|13|735|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8896|13|738|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8897|13|740|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8898|13|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8899|13|741|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8900|13|742|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8901|13|742|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8902|13|745|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8903|13|748|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8904|13|748|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8905|13|748|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8906|13|749|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8907|13|749|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8908|13|751|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8909|13|752|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8910|13|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8911|13|755|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8912|13|757|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8913|13|757|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8914|13|759|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8915|13|762|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8916|13|762|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8917|13|762|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8918|13|762|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8919|13|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8920|13|763|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8921|13|763|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8922|13|764|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8923|13|766|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8924|13|766|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8925|13|769|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8926|13|769|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8927|13|770|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8928|13|771|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8929|13|771|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8930|13|774|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8931|13|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8932|13|776|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8933|13|776|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8934|13|778|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8935|13|779|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8936|13|779|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8937|13|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8938|13|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8939|13|784|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8940|13|784|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8941|13|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8942|13|785|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8943|13|787|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8944|13|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8945|13|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8946|13|792|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8947|13|794|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8948|13|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8949|13|797|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8950|13|797|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8951|13|798|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8952|13|798|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8953|13|799|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8954|13|799|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8955|13|804|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8956|13|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8957|13|807|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8958|13|807|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8959|13|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8960|13|811|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8961|13|811|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8962|13|811|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8963|13|813|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8964|13|815|Neoplasia malignant|Adrenal gland  among endocrine systems|TADRC|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8965|13|821|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8966|13|821|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8967|13|825|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8968|13|826|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8969|13|833|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8970|13|836|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8971|13|839|Other deterministic changes|Whole body|NVL|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8972|13|839|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8973|13|841|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8974|13|843|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8975|13|843|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8976|13|844|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8977|13|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8978|13|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8979|13|847|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8980|13|848|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8981|13|848|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8982|13|854|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8983|13|858|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8984|13|875|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8985|13|889|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8986|13|895|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8987|13|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8988|13|901|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8989|13|905|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8990|13|906|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8991|13|906|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8992|13|908|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8993|13|909|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8994|13|926|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8995|13|940|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-13|C3Hf/Bd female mice 1.0 Gy exposure at 10 weeks,C3F100|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-13-8996|13|984|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-8997|14|66|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-8998|14|162|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-8999|14|212|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9000|14|227|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9001|14|240|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9002|14|380|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9003|14|409|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9004|14|420|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9005|14|438|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9006|14|440|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9007|14|444|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPIT,MPATH: 218 - neoplasm|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9008|14|475|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9009|14|475|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9010|14|489|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9011|14|503|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9012|14|505|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|TPANC,MPATH: 268 - adenocarcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9013|14|512|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9014|14|514|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9015|14|517|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9016|14|524|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9017|14|531|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9018|14|531|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9019|14|542|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9020|14|549|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9021|14|560|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9022|14|562|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9023|14|568|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9024|14|573|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9025|14|573|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9026|14|577|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9027|14|582|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9028|14|587|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9029|14|587|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9030|14|594|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9031|14|596|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9032|14|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9033|14|601|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9034|14|601|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9035|14|601|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9036|14|605|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9037|14|609|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9038|14|610|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9039|14|612|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9040|14|613|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9041|14|615|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9042|14|615|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9043|14|618|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9044|14|618|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9045|14|619|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9046|14|629|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9047|14|629|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9048|14|629|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9049|14|630|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9050|14|636|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9051|14|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9052|14|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9053|14|638|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9054|14|640|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9055|14|643|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9056|14|643|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9057|14|647|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9058|14|651|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9059|14|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9060|14|653|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9061|14|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9062|14|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9063|14|657|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9064|14|659|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9065|14|659|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9066|14|660|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9067|14|660|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9068|14|661|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9069|14|664|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9070|14|665|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9071|14|667|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9072|14|667|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9073|14|668|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9074|14|669|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9075|14|669|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9076|14|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9077|14|673|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9078|14|673|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9079|14|674|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9080|14|678|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9081|14|678|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9082|14|678|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9083|14|680|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9084|14|680|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9085|14|681|Neoplasia malignant|Endocrine system|THARC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9086|14|683|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9087|14|688|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9088|14|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9089|14|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9090|14|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9091|14|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9092|14|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9093|14|694|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9094|14|695|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9095|14|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9096|14|699|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9097|14|700|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9098|14|701|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9099|14|706|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9100|14|707|Neoplasia malignant|Endocrine system|THARC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9101|14|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9102|14|713|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9103|14|717|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9104|14|720|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9105|14|720|Neoplasia malignant|Endocrine system|THARC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9106|14|721|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9107|14|722|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9108|14|723|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9109|14|723|Neoplasia benign|Endocrine system|THARA|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9110|14|723|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9111|14|727|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9112|14|727|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9113|14|728|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9114|14|728|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9115|14|729|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9116|14|730|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9117|14|731|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9118|14|733|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9119|14|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9120|14|734|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9121|14|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9122|14|734|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9123|14|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9124|14|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9125|14|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9126|14|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9127|14|737|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9128|14|740|Neoplasia benign|Endocrine system|THARA|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9129|14|741|Neoplasia benign|Endocrine system|THARA|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9130|14|742|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9131|14|744|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9132|14|745|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9133|14|747|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9134|14|747|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9135|14|747|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9136|14|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9137|14|748|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9138|14|750|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9139|14|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9140|14|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9141|14|752|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9142|14|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9143|14|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9144|14|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9145|14|759|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9146|14|761|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9147|14|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9148|14|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9149|14|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9150|14|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9151|14|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9152|14|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9153|14|768|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9154|14|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9155|14|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9156|14|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9157|14|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9158|14|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9159|14|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9160|14|771|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9161|14|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9162|14|773|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9163|14|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9164|14|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9165|14|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9166|14|777|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9167|14|777|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9168|14|777|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9169|14|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9170|14|783|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9171|14|784|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9172|14|784|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9173|14|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9174|14|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9175|14|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9176|14|790|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9177|14|793|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9178|14|794|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9179|14|794|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9180|14|797|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9181|14|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9182|14|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9183|14|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9184|14|801|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9185|14|802|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9186|14|805|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9187|14|806|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9188|14|812|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9189|14|813|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9190|14|813|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9191|14|816|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9192|14|819|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9193|14|819|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9194|14|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9195|14|826|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9196|14|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9197|14|827|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9198|14|827|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9199|14|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9200|14|828|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9201|14|830|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9202|14|830|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9203|14|833|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9204|14|833|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9205|14|833|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9206|14|836|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9207|14|842|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9208|14|843|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9209|14|846|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9210|14|847|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9211|14|850|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9212|14|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9213|14|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9214|14|853|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9215|14|861|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9216|14|865|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9217|14|868|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9218|14|871|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9219|14|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9220|14|874|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9221|14|887|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9222|14|889|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9223|14|889|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9224|14|898|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9225|14|899|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9226|14|901|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9227|14|902|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9228|14|905|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9229|14|923|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9230|14|930|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9231|14|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9232|14|941|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9233|14|946|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9234|14|948|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9235|14|948|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9236|14|951|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9237|14|954|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9238|14|970|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9239|14|974|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9240|14|975|Other deterministic changes|Whole body|NVL|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9241|14|975|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9242|14|983|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9243|14|983|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9244|14|1000|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-14|C3Hf/Bd male mice 1.0 Gy exposure at 10 weeks,C3M100B|1|70|gamma-rays Cs-137|1|grays|External exposure|Single exposure|249 (249 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-14-9245|14|1049|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9246|15|297|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9247|15|310|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9248|15|339|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9249|15|366|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9250|15|379|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9251|15|386|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9252|15|394|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9253|15|394|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9254|15|408|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9255|15|409|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9256|15|419|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9257|15|427|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9258|15|430|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9259|15|430|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9260|15|433|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9261|15|440|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9262|15|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9263|15|442|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9264|15|447|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9265|15|447|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9266|15|448|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9267|15|448|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9268|15|449|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9269|15|450|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9270|15|451|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9271|15|451|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9272|15|454|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9273|15|458|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9274|15|461|Neoplasia malignant|Endocrine system|THARC|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9275|15|468|Neoplasia systemic|Haematolymphatic system|LMYL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9276|15|472|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9277|15|472|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9278|15|475|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9279|15|479|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9280|15|491|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9281|15|496|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9282|15|496|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9283|15|506|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9284|15|517|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9285|15|520|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9286|15|521|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9287|15|521|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9288|15|521|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9289|15|527|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9290|15|528|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9291|15|528|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9292|15|531|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9293|15|538|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9294|15|540|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9295|15|547|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9296|15|548|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9297|15|554|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9298|15|563|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9299|15|568|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9300|15|576|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9301|15|576|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9302|15|582|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9303|15|584|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9304|15|587|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9305|15|587|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9306|15|587|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9307|15|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9308|15|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9309|15|594|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9310|15|594|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9311|15|598|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9312|15|598|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9313|15|598|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9314|15|600|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9315|15|603|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9316|15|606|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9317|15|609|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9318|15|611|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9319|15|611|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9320|15|612|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9321|15|617|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9322|15|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9323|15|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9324|15|619|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9325|15|619|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9326|15|619|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9327|15|619|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9328|15|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9329|15|625|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9330|15|632|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9331|15|633|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9332|15|635|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9333|15|637|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9334|15|637|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9335|15|640|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9336|15|644|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9337|15|646|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9338|15|646|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9339|15|647|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9340|15|650|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9341|15|650|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9342|15|651|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9343|15|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9344|15|653|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9345|15|653|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9346|15|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9347|15|666|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9348|15|667|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9349|15|667|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9350|15|668|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9351|15|669|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9352|15|671|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9353|15|671|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9354|15|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9355|15|675|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBON|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9356|15|675|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9357|15|678|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9358|15|678|Neoplasia malignant|Endocrine system|THYRC|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9359|15|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9360|15|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9361|15|681|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9362|15|682|Other deterministic changes|Whole body|NVL|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9363|15|685|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9364|15|685|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9365|15|685|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9366|15|686|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9367|15|687|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9368|15|689|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9369|15|690|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9370|15|693|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9371|15|696|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9372|15|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9373|15|696|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9374|15|699|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9375|15|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9376|15|699|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9377|15|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9378|15|702|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9379|15|702|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9380|15|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9381|15|703|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9382|15|706|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9383|15|706|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9384|15|707|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9385|15|710|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9386|15|710|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9387|15|710|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9388|15|710|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9389|15|713|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9390|15|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9391|15|716|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9392|15|717|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9393|15|717|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9394|15|720|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9395|15|721|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9396|15|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9397|15|724|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9398|15|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9399|15|729|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9400|15|729|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9401|15|730|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9402|15|732|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9403|15|734|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9404|15|735|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9405|15|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9406|15|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9407|15|736|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9408|15|737|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9409|15|737|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9410|15|742|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9411|15|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9412|15|744|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9413|15|744|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9414|15|746|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9415|15|750|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9416|15|750|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9417|15|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9418|15|750|Neoplasia malignant|Endocrine system|THARC|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9419|15|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9420|15|757|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9421|15|758|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9422|15|758|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9423|15|758|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9424|15|758|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9425|15|759|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9426|15|759|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9427|15|760|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9428|15|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9429|15|764|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9430|15|769|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9431|15|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9432|15|776|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9433|15|776|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9434|15|777|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9435|15|779|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9436|15|779|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9437|15|779|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9438|15|781|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9439|15|784|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9440|15|786|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9441|15|787|Neoplasia benign|Endocrine system|THARA|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9442|15|790|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9443|15|790|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9444|15|791|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9445|15|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9446|15|797|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9447|15|797|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9448|15|798|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9449|15|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9450|15|804|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9451|15|804|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9452|15|806|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9453|15|807|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9454|15|808|Neoplasia malignant|Endocrine system|THARC|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9455|15|808|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9456|15|809|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9457|15|811|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9458|15|812|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9459|15|812|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9460|15|813|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9461|15|813|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9462|15|816|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9463|15|818|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9464|15|819|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9465|15|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9466|15|820|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9467|15|822|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9468|15|825|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9469|15|825|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9470|15|826|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9471|15|826|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9472|15|827|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9473|15|827|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9474|15|832|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9475|15|832|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9476|15|832|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9477|15|835|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9478|15|838|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9479|15|841|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9480|15|845|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9481|15|846|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9482|15|850|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9483|15|853|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9484|15|861|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9485|15|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9486|15|876|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9487|15|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9488|15|896|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9489|15|896|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9490|15|901|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9491|15|904|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9492|15|908|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9493|15|909|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9494|15|918|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9495|15|925|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9496|15|933|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9497|15|945|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9498|15|958|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9499|15|966|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9500|15|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9501|15|983|Neoplasia unclassified|Kidney among urinary system diseases,MA: 0000368 - kidney|TKID,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9502|15|1005|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOV,MPATH: 218 - neoplasm|
1007-2-15|C3Hf/Bd female mice 2.0 Gy exposure at 10 weeks,C3F200|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|258 (258 in ERA)|Mouse|Mouse, C3Hf/Bd|Female|need def 11|n/a|1007-2-15-9503|15|1028|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9504|16|174|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9505|16|301|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9506|16|322|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9507|16|348|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9508|16|365|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|TSAL,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9509|16|377|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9510|16|378|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9511|16|394|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9512|16|398|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|TSTOMA,MPATH: 551 - sarcoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9513|16|398|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9514|16|405|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9515|16|416|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TBST,MPATH: 218 - neoplasm|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9516|16|419|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9517|16|423|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9518|16|426|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9519|16|437|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9520|16|451|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9521|16|479|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9522|16|490|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9523|16|497|Neoplasia systemic|Haematolymphatic system|LMYL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9524|16|499|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9525|16|507|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9526|16|519|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9527|16|520|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9528|16|541|Neoplasia malignant|Endocrine system|THARC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9529|16|545|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9530|16|547|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9531|16|548|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9532|16|548|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9533|16|552|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9534|16|559|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9535|16|562|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LLYM,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9536|16|562|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9537|16|568|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9538|16|568|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9539|16|568|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9540|16|570|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9541|16|574|Neoplasia benign|Bloodvessels among cardiovascular system|TVASH|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9542|16|575|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9543|16|577|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9544|16|580|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9545|16|580|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9546|16|584|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9547|16|587|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9548|16|589|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9549|16|591|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9550|16|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9551|16|593|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKIDC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9552|16|594|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9553|16|595|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9554|16|596|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9555|16|597|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9556|16|597|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9557|16|600|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9558|16|601|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9559|16|602|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9560|16|602|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9561|16|603|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9562|16|605|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9563|16|607|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9564|16|608|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9565|16|608|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9566|16|610|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9567|16|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9568|16|612|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TOTH,MPATH: 218 - neoplasm|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9569|16|615|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9570|16|615|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9571|16|615|Neoplasia malignant|Endocrine system|THARC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9572|16|615|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9573|16|621|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9574|16|622|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9575|16|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9576|16|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9577|16|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9578|16|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9579|16|622|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9580|16|623|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9581|16|623|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9582|16|624|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9583|16|626|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9584|16|626|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9585|16|629|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9586|16|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9587|16|632|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9588|16|632|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9589|16|632|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9590|16|633|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9591|16|636|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9592|16|636|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9593|16|638|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKIDC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9594|16|639|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9595|16|639|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9596|16|640|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9597|16|644|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9598|16|644|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9599|16|645|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9600|16|646|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9601|16|650|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9602|16|651|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9603|16|651|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9604|16|653|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9605|16|654|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9606|16|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9607|16|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9608|16|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9609|16|657|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9610|16|664|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9611|16|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9612|16|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9613|16|671|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9614|16|671|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9615|16|672|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9616|16|672|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9617|16|674|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9618|16|675|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9619|16|678|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9620|16|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9621|16|679|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9622|16|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9623|16|681|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9624|16|686|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9625|16|687|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9626|16|689|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9627|16|692|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9628|16|693|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9629|16|694|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9630|16|694|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9631|16|694|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9632|16|695|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9633|16|696|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9634|16|696|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9635|16|696|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9636|16|699|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9637|16|699|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9638|16|700|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9639|16|702|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9640|16|703|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9641|16|706|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9642|16|715|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9643|16|715|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9644|16|716|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9645|16|716|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9646|16|717|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9647|16|720|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9648|16|722|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9649|16|723|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9650|16|724|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9651|16|724|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9652|16|727|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9653|16|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9654|16|728|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9655|16|730|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9656|16|731|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9657|16|734|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9658|16|734|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9659|16|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9660|16|736|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9661|16|739|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9662|16|741|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9663|16|742|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9664|16|743|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9665|16|744|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9666|16|745|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9667|16|745|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9668|16|747|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9669|16|748|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9670|16|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9671|16|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9672|16|750|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9673|16|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9674|16|751|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9675|16|755|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9676|16|755|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9677|16|756|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9678|16|760|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9679|16|762|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9680|16|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9681|16|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9682|16|762|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9683|16|763|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9684|16|764|Neoplasia malignant|Liver among hepato-pancreatic system diseases|TLIVC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9685|16|764|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9686|16|764|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9687|16|765|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9688|16|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9689|16|769|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9690|16|770|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9691|16|770|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9692|16|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9693|16|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9694|16|773|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9695|16|774|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9696|16|774|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9697|16|776|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9698|16|778|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9699|16|778|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9700|16|778|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9701|16|780|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9702|16|780|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9703|16|780|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9704|16|783|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9705|16|783|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TLUNC,MPATH: 549 - carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9706|16|785|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9707|16|785|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9708|16|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9709|16|787|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9710|16|789|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9711|16|790|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9712|16|793|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9713|16|796|Neoplasia benign|Endocrine system|THARA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9714|16|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9715|16|797|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9716|16|799|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9717|16|801|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9718|16|801|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9719|16|806|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9720|16|811|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9721|16|814|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9722|16|814|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9723|16|815|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9724|16|816|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9725|16|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9726|16|818|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9727|16|819|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9728|16|820|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9729|16|820|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9730|16|821|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9731|16|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9732|16|829|Neoplasia malignant|Endocrine system|THARC|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9733|16|832|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9734|16|839|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9735|16|839|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9736|16|839|Neoplasia malignant|Bloodvessels among cardiovascular system|TVASS|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9737|16|856|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9738|16|856|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9739|16|857|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9740|16|858|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|TSQC,MPATH: 446 - squamous cell carcinoma|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9741|16|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|LRCS,MPATH: 513 - Lymphoid neoplasms|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9742|16|877|Neoplasia benign|Lower respiratory system|TLUNA|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9743|16|883|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9744|16|883|Neoplasia malignant|Other local manifestations and miscellaneus|TSAR|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9745|16|888|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9746|16|891|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9747|16|898|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9748|16|911|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9749|16|911|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9750|16|945|Other deterministic changes|Whole body|NVL|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9751|16|954|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9752|16|966|Neoplasia benign|Liver among hepato-pancreatic system diseases|THEP|
1007-2-16|C3Hf/Bd male mice 2.0 Gy exposure at 10 weeks,C3M200B|1|70|gamma-rays Cs-137|2|grays|External exposure|Single exposure|250 (250 in ERA)|Mouse|Mouse, C3Hf/Bd|Male|need def 11|n/a|1007-2-16-9753|16|1059|Other deterministic changes|Whole body|NVL|
